Literature DB >> 11850742

When an erection alone is not enough: biopsychosocial obstacles to lovemaking.

S E Althof1.   

Abstract

Giving men firm erections is relatively straightforward these days; getting them to make use of it regularly in lovemaking is more complicated. Discontinuation rates for any of the available medical treatments for erectile dysfunction, including sildenafil, have been found to range from 50% to 60%. Thus, there is a disproportionately high number of individuals who fail to continue using medical interventions compared to those for whom treatment is efficacious. If not efficacy, then what factors contribute to this puzzling dropout phenomenon? This article discusses the psychological resistances of men, women, and couples that contribute to their stopping treatment for erectile dysfunction. Some of the factors that may be responsible include: (1) the length of time the couple was asexual before seeking treatment; (2) the man's approach to resuming a sexual life with his partner; (3) the man's expectations of how sildenafil will change his life; (4) the partner's physical and emotional readiness to resume lovemaking; (5) the meaning for each partner of using a medical intervention to restore lovemaking; (6) the quality of the nonsexual relationship; and (7) unconventional sexual arousal patterns in the man. To be effective, clinicians must go beyond the simple restoration of erectile function to help patients become active lovemakers again.

Entities:  

Mesh:

Year:  2002        PMID: 11850742     DOI: 10.1038/sj.ijir.3900799

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  28 in total

Review 1.  Treating erectile dysfunction when PDE5 inhibitors fail.

Authors:  Chelsea N McMahon; Christopher J Smith; Ridwan Shabsigh
Journal:  BMJ       Date:  2006-03-11

2.  ED and quality of life in CABG patients: an intervention study using PRECEDE-PROCEED educational program.

Authors:  S Pournaghash-Tehrani; S Etemadi
Journal:  Int J Impot Res       Date:  2013-06-13       Impact factor: 2.896

3.  Sexual medicine: Why stop a good thing? Discontinuing PDE5 inhibitors.

Authors:  Helen M Conaglen; John V Conaglen
Journal:  Nat Rev Urol       Date:  2012-08-14       Impact factor: 14.432

4.  Sexual medicine: the psychological effects of recreational PDE5 inhibitor use.

Authors:  Tamara Melnik
Journal:  Nat Rev Urol       Date:  2012-07-31       Impact factor: 14.432

5.  Data on the utilization of treatment modalities for ED in Taiwan in the era of PDE5 inhibitors.

Authors:  W-K Tsai; B-P Jiann
Journal:  Int J Impot Res       Date:  2014-01-23       Impact factor: 2.896

Review 6.  Psychosocial perspectives on sexual recovery after prostate cancer treatment.

Authors:  Lauren M Walker; Richard J Wassersug; John W Robinson
Journal:  Nat Rev Urol       Date:  2015-03-10       Impact factor: 14.432

Review 7.  A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 8.  Psychosocial contributors to patients' and partners' postprostate cancer sexual recovery: 10 evidence-based and practical considerations.

Authors:  Lauren M Walker
Journal:  Int J Impot Res       Date:  2020-11-17       Impact factor: 2.896

Review 9.  Psychotherapy for erectile dysfunction: now more relevant than ever.

Authors:  Stanley E Althof; Miki Wieder
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.633

Review 10.  Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

Authors:  R Sadovsky; G B Brock; S W Gutkin; S Sorsaburu
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.